How to access Ctexli for cerebrotendinous xanthomatosis from Abu Dhabi: 2026 pathway via SSMC, CCAD, Tawam, and SKMC metabolic-genetics | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Abu Dhabi holds the UAE's strongest in-emirate metabolic-genetics and adult-neurology depth at SSMC, CCAD, Tawam Hospital, SKMC, and Burjeel Medical City. CTX cases identified within Abu Dhabi are confirmed in-emirate and managed in-emirate. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement therapy for CTX.
Why Ctexli, why now
Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts bile-acid synthesis and leads to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and cognitive decline. Most patients develop neurologic symptoms in the second or third decade if untreated.
The 2026 question for an Abu Dhabi patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with the Emirates Drug Establishment (EDE), so the pathway is named-patient personal-import authorisation under EDE.
What Ctexli is, in plain language
Ctexli is an oral chenodiol capsule. Mechanistically it replaces the bile acid (chenodeoxycholic acid) the patient's deficient enzyme cannot make and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, lowering accumulated cholestanol. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.
Access pathway in Abu Dhabi
The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance. The Department of Health Abu Dhabi (DoH Abu Dhabi) governs healthcare facility licensing in the emirate. Ctexli is not currently EDE-registered. Access runs through an EDE-approved named-patient personal-import authorisation, with DoH Abu Dhabi acknowledgment, filed by the treating clinician at SSMC, CCAD, Tawam, SKMC, or Burjeel Medical City. Abu Dhabi holds the UAE's strongest in-emirate metabolic-genetics and adult-neurology depth: the CCAD genetic disease programme, SSMC metabolic clinic, Tawam paediatric and adult neurology, and SKMC paediatric neurology each handle confirmation and management.
The treating neurologist or metabolic specialist submits the named-patient import application documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Abu Dhabi International Airport.
Eligibility at an Abu Dhabi metabolic-genetics or neurology clinic
Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features).
Documentation required
The patient and physician should be prepared to provide: a current Emirates ID or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the EDE named-patient import application; the DoH Abu Dhabi acknowledgment; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
The annual cost band for Ctexli in Abu Dhabi is USD 150,000 to 220,000 per patient (AED 550,000 to 810,000), weight-dependent, lifelong. Pre-approval, CTX patients in the region were typically maintained on compounded chenodeoxycholic acid at substantially lower cost; FDA-approved Ctexli carries a manufacturer premium. Thiqa coverage for Emirati nationals applies on a case-by-case basis under the rare-disease provision with the treating specialist's documentation. Daman Enhanced, AXA Gulf, Allianz, MetLife, and BUPA Arabia plans typically require pre-authorisation with the genetics confirmation and a treating-specialist letter; coverage for an unregistered ultra-orphan agent is unusual but not impossible.
Typical timeline
Weeks 0 to 4: confirm diagnosis, prescription preparation, EDE import filing through the Abu Dhabi hospital pharmacy. Weeks 4 to 8: shipment arrival at Abu Dhabi International Airport, initiation under metabolic-genetics or neurology supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, and tolerability monitoring. Months 6 and 12: full metabolic and neurologic reassessment, repeat plasma cholestanol, and brain MRI white-matter assessment.
When Ctexli is the wrong drug
Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment.
Frequently asked questions
- Is the pathway legal in Abu Dhabi? Yes. It operates under EDE named-patient personal-import authorisation with DoH Abu Dhabi acknowledgment under federal UAE medicines law.
- Will Thiqa or my insurance cover Ctexli? Emirati nationals may secure Thiqa rare-disease case-by-case support; private insurance coverage for ultra-orphan agents is unusual but pre-authorisation with documented genetics is the path to attempt.
- How long does treatment continue? Lifelong. CTX is a chronic genetic disease.
- Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
- What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
- Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in Abu Dhabi are managed at Tawam, CCAD, SSMC, or SKMC paediatric neurology.
Closing
Reserve Meds runs the Ctexli supply file from the Abu Dhabi metabolic-genetics or neurology referral through EDE named-patient authorisation, US or EU sourcing, and delivered emirate supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.